Gather-ed - The Multiple Myeloma Patient Journey

Target Professions:	MD, DO, Nurse, Nurse Practitioner, Pharmacist, Physician Assistant
Target Specialties:	Hematology, Hematology/Oncology, Oncology
Credits Available:	3.25 AMA PRA Category 1 Credit™

Multiple myeloma is the second-most-common hematologic malignancy in the United States with approximately 34,470 new cases diagnosed in the United States in 2022. Although multiple myeloma is an incurable disease, numerous active agents are available that, when used in combination, often lead to deep and durable remissions however, the majority of patients with multiple myeloma will eventually relapse. As a result, there has been a dramatic increase in the complexity of care for patients with relapsed/refractory multiple myeloma. To address these gaps and improve the practice of clinicians who treat patients with relapsed/refractory multiple myeloma, this educational intervention will facilitate exchange of information, clinical experience, and practical guidance, while establishing sustainable support networks between the multidisciplinary healthcare team.

CME/CE Accreditation Information

Itinerary

Part 1 - Baseline Assessment, Self Study, Live Group Discussion, Final Assessment

The Multiple Myeloma Patient Journey - Baseline Assessment

This assessment will provide a baseline measure of your knowledge of best practices in relapsed/refractory multiple myeloma treatment.

Module 1: Treatment Selection and Sequencing in Early Relapse

This case will discuss the journey of a 56-year-old male patient with newly diagnosed multiple myeloma who, after 2.5 years of maintenance therapy, relapses and works with his hematology/oncology specialist to select his next treatment.

Module 2: Treatment Selection and Sequencing in Late Relapse

This case will review the journey of a 41 year old male patient with quadruple-refractory multiple myeloma who works with his hematology/oncology specialist to select the next steps in his MM treatment journey.

Final Assessment: The Multiple Myeloma Patient Journey

This post-activity assessment will ascertain the knowledge gained as a result of your participation in this initiative.

Lessons Learned and Ongoing Challenges

The group will discuss key points from each of the preceding modules, as well as group challenge submissions and general comments.

Part 2 - Group Challenge, Action Plan, Live Group Discussion

Case Study 1 - Maeve, a 62-year-old African American female

This group case discussion will discuss treatment selection and sequencing challenges for a patient with R-ISS, stage II, IgG lambda multiple myeloma (MM) in the early relapse setting.

Case Study 2 - Akamu, a 57-year-old Polynesian male

In this group activity, learners will discuss treatment selection and sequencing challenges in the case of a patient with R-ISS, stage II, hyperdiploid multiple myeloma (MM).

Your Action Plan in Multiple Myeloma

In light of the information reviewed and discussed during this program, can you share an action plan that you will implement to improve the outcomes for your patients with relapsed or refractory multiple myeloma (RRMM).

Discussion of Group Challenges and Action Plans

The group will discuss the group challenges, their action plans, and barriers to implementation while receiving real-time feedback from the group leader and other group members.

Curriculum is Currently Closed

Thank you for your interest. Currently, the curriculum is closed for enrollment but we encourage you to keep an eye out for future opportunities or alternative programs that might align with your educational goals.

View Other Offerings